NASDAQ:BLRX BioLineRx (BLRX) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free BLRX Stock Alerts $1.11 +0.08 (+7.77%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$1.06▼$1.1250-Day Range$1.03▼$1.3952-Week Range$0.81▼$2.53Volume347,058 shsAverage Volume324,050 shsMarket Capitalization$80.41 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioLineRx alerts: Email Address BioLineRx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,791.9% Upside$21.00 Price TargetShort InterestHealthy0.45% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.98) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.98 out of 5 starsMedical Sector617th out of 939 stocksPharmaceutical Preparations Industry283rd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingBioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, BioLineRx has a forecasted upside of 1,791.9% from its current price of $1.11.Amount of Analyst CoverageBioLineRx has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.45% of the outstanding shares of BioLineRx have been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioLineRx has recently increased by 76.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioLineRx does not currently pay a dividend.Dividend GrowthBioLineRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLRX. Previous Next 3.1 News and Social Media Coverage News SentimentBioLineRx has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for BioLineRx this week, compared to 1 article on an average week.Search Interest11 people have searched for BLRX on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.MarketBeat Follows11 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLineRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of BioLineRx is held by insiders.Percentage Held by InstitutionsOnly 1.56% of the stock of BioLineRx is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLineRx are expected to grow in the coming year, from ($0.98) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLineRx is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLineRx is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLineRx has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About BioLineRx Stock (NASDAQ:BLRX)BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.Read More BLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLRX Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comBioLineRx (NASDAQ:BLRX) Upgraded by StockNews.com to "Sell"March 27, 2024 | finance.yahoo.comBioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 27, 2024 | finance.yahoo.comBLRX: First Aphexda Sales RecognizedMarch 27, 2024 | americanbankingnews.comBioLineRx's (BLRX) "Buy" Rating Reaffirmed at HC WainwrightMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioLineRx: Strong Financials and Expanding Market Presence Fuel Analyst OptimismMarch 26, 2024 | prnewswire.comBioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio UpdatesMarch 24, 2024 | americanbankingnews.comBioLineRx (BLRX) Scheduled to Post Earnings on TuesdayMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 20, 2024 | prnewswire.comBioLineRx to Report 2023 Annual Financial Results on March 26, 2024March 4, 2024 | finance.yahoo.comBioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale ProductionMarch 1, 2024 | investing.comBioLineRx begins phase 2 trial for pancreatic cancer treatmentMarch 1, 2024 | finance.yahoo.comBLRX Mar 2024 1.000 callFebruary 28, 2024 | prnewswire.comBioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)February 26, 2024 | finance.yahoo.comBLRX: Poster PresentationsFebruary 25, 2024 | investorplace.com3 Top Penny Stocks for 5,000% Upside in 2024 and BeyondFebruary 23, 2024 | ca.finance.yahoo.comBLRX May 2024 1.000 putFebruary 16, 2024 | finance.yahoo.comBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®February 16, 2024 | prnewswire.comBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®December 21, 2023 | finance.yahoo.comBioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell DiseaseDecember 4, 2023 | seekingalpha.comBioLineRx: Still A Buy, With Some QuestionsDecember 3, 2023 | seekingalpha.comBioLineRx: Weighing Aphexda's Breakthrough Against Financial ChallengesNovember 21, 2023 | insidermonkey.comBioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call TranscriptNovember 21, 2023 | markets.businessinsider.comBioline RX Receives Buy Rating Despite Lower Than Expected Q3 Results: Expansions, Partnerships, and Promising Clinical Trials Signal Future GrowthNovember 21, 2023 | finance.yahoo.comBLRX: A Series of Fortunate EventsNovember 20, 2023 | finance.yahoo.comBioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio UpdatesNovember 17, 2023 | msn.combiolinerx Q3 2023 Earnings PreviewSee More Headlines Receive BLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today3/28/2024Next Earnings (Estimated)5/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BLRX CUSIPN/A CIK1498403 Webwww.biolinerx.com Phone(728) 642-9100Fax972-8642-9101Employees49Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+1,791.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-169.03% Return on Assets-81.71% Debt Debt-to-Equity Ratio0.64 Current Ratio1.96 Quick Ratio1.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book1.34Miscellaneous Outstanding Shares72,440,000Free Float71,642,000Market Cap$80.41 million OptionableOptionable Beta1.40 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Philip A. Serlin CPA (Age 64)M.B.A., CPA, MBA, Chief Executive Officer Comp: $635kMs. Mali Zeevi CPA (Age 48)CPA, Chief Financial Officer Comp: $380kDr. Ella Sorani (Age 56)Chief Development Officer Comp: $457kMs. Holly W. May M.B.A. (Age 62)President of BioLineRx USA Comp: $328kMr. John LaceyHead of Corporate Communications & Investor RelationsMr. Adam Janoff Esq.General Counsel & Head of ComplianceMs. Tsipi Keren-Lehrer B.Sc.L.L.B., Head of BD & Strategic AdvisorMr. Raziel FriedTreasurer & Budgetary Control DirectorMore ExecutivesKey CompetitorsEliem TherapeuticsNASDAQ:ELYMOncolytics BiotechNASDAQ:ONCYEnlivex TherapeuticsNASDAQ:ENLVConnect BiopharmaNASDAQ:CNTBEquilliumNASDAQ:EQView All CompetitorsInstitutional OwnershipPVG Asset Management CorpBought 61,840 shares on 3/12/2024Ownership: 0.085%Citadel Advisors LLCBought 200 shares on 2/15/2024Ownership: 0.000%Envestnet Asset Management Inc.Sold 11,488 shares on 2/13/2024Ownership: 0.064%NorthRock Partners LLCBought 17,125 shares on 2/8/2024Ownership: 0.024%View All Institutional Transactions BLRX Stock Analysis - Frequently Asked Questions Should I buy or sell BioLineRx stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BLRX shares. View BLRX analyst ratings or view top-rated stocks. What is BioLineRx's stock price target for 2024? 1 analysts have issued 1 year target prices for BioLineRx's stock. Their BLRX share price targets range from $21.00 to $21.00. On average, they anticipate the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 1,791.9% from the stock's current price. View analysts price targets for BLRX or view top-rated stocks among Wall Street analysts. How have BLRX shares performed in 2024? BioLineRx's stock was trading at $1.57 at the start of the year. Since then, BLRX shares have decreased by 29.3% and is now trading at $1.11. View the best growth stocks for 2024 here. Are investors shorting BioLineRx? BioLineRx saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 324,700 shares, an increase of 76.6% from the February 29th total of 183,900 shares. Based on an average daily volume of 316,300 shares, the short-interest ratio is currently 1.0 days. View BioLineRx's Short Interest. When is BioLineRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our BLRX earnings forecast. How were BioLineRx's earnings last quarter? BioLineRx Ltd. (NASDAQ:BLRX) announced its quarterly earnings results on Tuesday, March, 26th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07. The biotechnology company had revenue of $4.80 million for the quarter, compared to analyst estimates of $0.17 million. During the same period last year, the firm posted ($0.09) earnings per share. What other stocks do shareholders of BioLineRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE). Who are BioLineRx's major shareholders? BioLineRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include PVG Asset Management Corp (0.09%), Envestnet Asset Management Inc. (0.06%), NorthRock Partners LLC (0.02%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of BioLineRx? Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLRX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.